Gastritis Market By Type (Acute Gastritis, Chronic Gastritis, Erosive Gastritis), By Drug Type (Antacids, Antibiotics, Cytoprotective Agents, Others), By Route of Administration (Oral, Parenteral), By End-User (Hospitals and Clinics, Specialty Centers, Homecare Settings), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032

Report Overview

Gastritis Market size is expected to be worth around USD 18.3 Bn by 2032 from USD 10.2 Bn in 2022, growing at a CAGR of 6.2% during the forecast period from 2023 to 2032.

Gastritis, a common medical condition characterized by inflammation of the stomach membrane, is caused by a multitude of complex factors. A few causes of gastritis include excessive alcohol consumption, chronic tension, and the administration of specific medications. Existing gastritis treatments include pharmacological interventions, dietary modifications, and changes in lifestyle, but a definitive cure remains illusive.

The ultimate goal of gastritis treatment is to reduce inflammation and alleviate the associated symptoms, which include excruciating pain, debilitating nausea, and persistent regurgitation. Gastritis has a significant impact on a person's overall health, and if left untreated, it can lead to dire health consequences.

However, gastritis can be effectively treated, preparing the way for improved patient outcomes, when subjected to the appropriate interventions. Recent advances in gastritis treatment include the introduction of innovative medications and cutting-edge diagnostic instruments. In addition, researchers are investigating the uncharted territory of microbiome-based therapies in an effort to uncover their potential for treating gastritis.

Pharmaceutical conglomerates, medical device manufacturers, and diagnostic enterprises have identified the immense potential in the field of gastritis treatment, prompting them to invest substantial capital in the development of novel therapeutic interventions. Nevertheless, as with any medical intervention, the ethical considerations surrounding the use of gastritis treatments require careful examination. Prioritizing patient-centered outcomes and an unwavering commitment to safety, it is of the utmost importance to ensure the responsible and ethical implementation of treatments.

Driving factors

High Global Prevalence

Gastritis is not an isolated health concern; it affects a substantial portion of the world's population. The sheer prevalence of gastritis creates a significant and consistent demand for medical interventions, diagnostic tools, and therapies. Healthcare providers and pharmaceutical companies are driven by the need to cater to this widespread health issue, making it a pivotal driver in the gastritis market.

Changing Dietary Patterns

Gastritis is closely tied to dietary habits. Evolving lifestyles and dietary patterns, such as increased alcohol consumption and the consumption of certain foods, can exacerbate gastritis symptoms. These shifts in dietary preferences present opportunities for market players to develop specialized products and services targeting gastritis-related concerns.

Advanced Diagnostic Methods

Recent advancements in diagnostic methods have revolutionized the way healthcare providers identify and treat gastritis. More precise and efficient diagnostic tools empower medical professionals to offer better-tailored treatment plans. This improvement not only enhances patient care but also encourages market growth by increasing the overall demand for these diagnostic technologies.

Technological Advancements

The integration of advanced technologies, such as telemedicine and remote patient monitoring, holds immense potential for transforming how gastritis is managed and treated. These technologies provide patients with improved access to healthcare services and offer healthcare providers new tools to enhance patient care, further stimulating market growth.

Restraining Factors

Variability in the Causes and Symptoms of Gastritis

Gastritis is an inflammation of the lining of the stomach that may be caused by bacterial infections, alcohol consumption, protracted use of nonsteroidal anti-inflammatory medications (NSAIDs), or stress-related factors. However, gastritis symptoms can differ considerably from person to person, making diagnosis and treatment difficult. Common symptoms of gastritis include nausea, vomiting, abdominal pain, bloating, appetite loss, and faeces that are soiled or dark in color. However, some individuals with gastritis may not experience any symptoms, while others may experience severe symptoms that require immediate medical attention.

Difficulties in Correct Diagnosis and Classification

Accurately diagnosing gastritis is one of the primary obstacles associated with its treatment. Endoscopy, an invasive procedure that involves inserting a tube with a camera through the mouth to examine the stomach lining for inflammation, is the only way to definitively diagnose gastritis. In addition to the difficulties associated with diagnosing gastritis, there are numerous categories of gastritis that require various treatments. Acute gastritis, chronic gastritis, and autoimmune gastritis are the most prevalent forms of gastritis. Due to the fact that each type has distinct symptoms and treatment options, accurate diagnosis and classification are essential for effective treatment.

Possible Adverse Effects of Medications

There are a number of medications available to treat gastritis, but some of them have adverse effects that may reduce their efficacy or cause additional complications. For instance, prolonged use of proton pump inhibitors (PPIs), which are commonly used to reduce gastric acid secretion, can result in diarrhea, headaches, and an increased risk of bone fractures. Similarly, antacids, which are used to neutralize gastric acid, can cause constipation or diarrhea and reduce the efficacy of other medications.

Alternative Therapies for Gastrointestinal Disorders as Rivals

Global Gastritis Market faces intense competition from alternative treatments for gastrointestinal disorders, such as home remedies, alternative medicine, and naturopathic therapies. Although these treatments may not be as effective as conventional medical treatments, they are frequently less expensive and may be more accessible to patients who cannot afford costly medical care.

Type Analysis

In terms of revenue share, the Acute Gastritis segment is dominating the market. This market segment is anticipated to experience the highest growth rate over the coming years. Acute gastritis is an inflammation of the lining of the stomach that can cause nausea, vomiting, abdominal discomfort, and swelling. Several factors contribute to the expansion of the acute gastritis segment of the global gastritis market.

The acute gastritis segment of the global gastritis market is experiencing a rising trend among consumers. This is due to the fact that acute gastritis effects a large number of individuals worldwide. This segment's development is being driven by the increasing prevalence of the disease and awareness of its treatment options. Moreover, there is a growing demand for minimally invasive remedies among consumers, which is driving demand for the acute gastritis segment. Increasing consumer demand for minimally invasive remedies is driving growth in the acute gastritis segment. All of these factors should contribute to the expansion of this segment of the global gastritis market.

Drug Type Analysis

In terms of revenue, the Antibiotics segment dominates the market. This market segment is anticipated to experience the highest growth rate over the coming years. Due to the efficacy of antibiotics in addressing the underlying cause of gastritis, their use has become widespread in the treatment of this condition. The antibiotics segment of the global gastritis market is experiencing a rising trend among consumers. This is due to the efficacy of antibiotics in treating the underlying cause of gastritis, which is frequently caused by the H. pylori bacterium.

The increasing prevalence of H. pylori infection is one of the primary factors driving growth of the antibiotics segment in the global gastritis market. In addition, the rise in economic development has led to a rise in the adoption of advanced treatments such as antibiotics, which is further increasing demand for this segment. Increasing consumer awareness of the benefits of antibiotics is anticipated to fuel the growth of this segment in the global gastritis market.

Route of Administration Analysis

In terms of market revenue share, the oral segment is dominant. This market segment is anticipated to experience the highest growth rate over the coming years. The most convenient and preferred route of administration for the treatment of gastritis is oral administration. The oral segment of the global gastritis market is gaining popularity among consumers. Because oral administration is the most convenient and preferable route of administration for the treatment of gastritis, this is the case.

One of the main factors propelling the growth of the oral segment in the global gastritis market is the increasing preference for oral administration. In addition, the rise in economic development has led to an increase in the use of oral medications, which is further bolstering the demand for this market segment. Increasing consumer awareness of the benefits of oral medications is anticipated to fuel the growth of this segment in the global gastritis market.

End-User Analysis

Revenue-wise, the hospitals and clinics segment dominates the market. This market segment is anticipated to experience the highest growth rate over the coming years. Due to their advanced infrastructure and availability of qualified healthcare professionals, hospitals and clinics are the preferred end-users for gastritis treatment. The hospitals and clinics segment of the global gastritis market is attracting a growing number of consumers. This is due to the fact that hospitals and clinics are equipped with sophisticated infrastructure and qualified medical personnel, allowing for effective gastritis treatment.

The increase in the number of gastritis patients is fueling the growth of the hospitals and clinics segment of the global gastritis market. In addition, the rise in economic development has led to a rise in the adoption of advanced remedies, such as hospitals and clinics, which is further increasing demand for this segment. Increasing consumer awareness of the benefits of healthcare professionals is anticipated to drive the expansion of this segment of the global gastritis market.

Key Market Segments

By Type

• Acute Gastritis
• Chronic Gastritis
• Erosive Gastritis
• Non-Erosive Gastritis

By Drug Type

• Antacids
• Antibiotics
• Cytoprotective Agents
• Prokinetics
• Otheres

By Route of Administration

• Oral
• Parenteral

By End-User

• Hospitals and Clinics
• Specialty Centers
• Homecare Settings

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Growth Opportunity

Ascent of Gastritis in the Global Market

In the extensive topography of digestive disorders, gastritis stands out as a prevalent ailment with untapped growth potential on the global market. This potential is fueled by a multitude of opportunities, such as the development of targeted therapies based on underlying causes, the expansion of diagnostic capabilities for H. pylori infection, research on personalized treatment approaches, and the effectiveness of collaboration between pharmaceutical companies and gastroenterologists.

Demand for Gastric Treatment Alternatives

Patients around the world are increasingly pursuing treatment for gastritis as the tide turns. This increase in demand stimulates the creation of novel therapeutic options. Antibiotics and proton pump inhibitors (PPIs) play a central role in the fight for H. pylori eradication and acid reduction. Their emergence is a reflection of the increasing demand for effective treatment options in the global gastritis market.

Seeking Accuracy in Diagnosis and Therapy

The medical community is beckoned to unravel the intricate fibers of gastritis' complex tapestry of causal factors. Contributing to its development are bacterial infections, protracted use of non-steroidal anti-inflammatory medications (NSAIDs), excessive alcohol consumption, and stress. Accurate diagnosis of the underlying cause is essential for effective treatment, as it enables the development of targeted therapies tailored to the individual patient's requirements.

Increasing Diagnostic Scope

Within the domain of gastritis, one factor stands out: the persistent infection with Helicobacter pylori. This elusive bacterium is a frequent cause of gastritis, requiring accurate identification for effective treatment. Herein lays a growth opportunity: expanding diagnostic capabilities. The advent of new, non-invasive diagnostic tests has the potential to bolster the global gastritis market by providing clinicians with improved H. pylori detection tools.

Journey of Customized Care

As knowledge and comprehension expand, the doors to personalized treatment approaches open wide. The ability to tailor treatment plans to the symptoms, medical histories, and unique circumstances of individual patients ushers in a new era. Personalization illuminates the path to a brighter future in gastritis care by paving the way for improved treatment outcomes and increased patient satisfaction.

Combining Forces for Advancement

Collaboration is a potent symphony in the domain of advancement. The alliance between pharmaceutical companies and gastroenterologists is essential for the development of novel gastritis treatments. The expertise and resources of pharmaceutical companies combine with the profound knowledge of gastroenterologists to create an environment conducive to innovation. Together, they advance, motivated by a shared vision of improving patient outcomes and reshaping the global landscape of gastritis.

Latest Trends

Medication for acid suppression paves the way

Within the domain of gastritis, a symphony of symptoms—abdominal pain, bloating, nausea, and vomiting—emerge, affecting a wide variety of patients. As the need for respite increases, acid-suppressing drugs assume center stage, providing solace in the face of pain. Proton pump inhibitors (PPIs) and H2-blockers emerge as illustrious allies by lowering gastric acid production. The increased demand for these medications is fueled by their rapid efficacy in providing gastritis patients with relief.

Duo of Antibiotic and Proton Pump Inhibitors

Helicobacter pylori (H. pylori) casts its shadow as a notorious bacterial infection in the intricate dance of gastritis. It affects nearly half of the world's population, necessitating immediate action. Effective management of gastritis requires the eradication of H. pylori, which is accomplished through the use of antibiotics and proton pump inhibitors. Amoxicillin, clarithromycin, and metronidazole compose a symphony, while proton pump inhibitors harmonize to reduce inflammation and acidity. The increasing prevalence of H. pylori infection drives demand for these effective allies.

Dietary and Lifestyle Adjustments

Patients with gastritis are urged to appreciate the transformative potential of dietary and lifestyle changes. A customized voyage transpires, encouraging the development of new habits. The path to symptom management is paved with the avoidance of fiery and acidic foods, the adoption of small and frequent meals, and adequate hydration. Adopting a healthy lifestyle, including regular exercise and stress management, forms the basis for preventing the recurrence of symptoms. Dietary and lifestyle modifications are prevalent in the management of gastritis due to the allure of cost-effective and effective solutions.

Methods of noninvasive diagnosis take center stage

In the pursuit of precise and timely diagnosis, non-invasive diagnostic techniques take center stage. Breath tests, stool antigen tests, and serological tests emerge as preferable alternatives to invasive techniques such as endoscopy, ushering in a new era. Their appeal stems from their simplicity, affordability, and speedy results. By adopting non-invasive diagnostic techniques, the global gastritis market will increase patient convenience and diagnostic efficacy.

Regional Analysis

Gastritis is a medical condition characterized by inflammation of the gastrointestinal membrane. It is an agonizing and uncomfortable condition that frequently causes nausea, vomiting, and abdominal discomfort. Europe holds the largest market share for the gastritis market, according to recent research. Let us investigate this trend in detail.

More than 30% of the global gastritis market is controlled by Europe, making it the market leader. Several factors, including the high prevalence of gastritis in the region, the availability of sophisticated therapeutics, and the extensive research being conducted in the field, contribute to the region's dominant position in the gastritis market.

Even though it is a prevalent condition, gastritis poses a significant problem in Europe, with an estimated incidence rate between 10 and 20% of the population. Several factors, including alcohol consumption, the use of non-steroidal anti-inflammatory medications (NSAIDs), Helicobacter pylori infection, and autoimmune disorders, contribute to the prevalence of gastritis.

Due to the high incidence rate, significant investment has been made in research on the condition, leading to the development of advanced therapeutics that effectively treat the disease. The increasing demand for advanced therapeutics has resulted in an increase in the demand for gastritis products in Europe, which has led to the region's dominant market position.

Recent therapeutic advancements in Europe have significantly contributed to the region's dominant position in the gastritis market. Advanced therapeutics that target the H. pylori bacteria that cause gastric ulcers and gastritis have been shown to be effective in achieving long-term disease remission. Significant progress has also been made in the treatment of gastritis with proton pump inhibitors (PPIs) such as omeprazole, lansoprazole, and pantoprazole, which act to reduce the quantity of acid produced in the stomach.

In the future years, the gastritis market in Europe is anticipated to expand significantly. The dominant position of the region in the market will continue to be supported by the high incidence rate of the disease, the rising demand for advanced therapeutics, and ongoing research into the disease. The increasing demand for natural and wellness-based solutions is also anticipated to impact the future of the European gastritis market, with herbal and natural remedies anticipated to gain prominence in the coming years.

Key Regions and Countries

North America

• US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

Global gastritis market has expanded significantly, with industry leaders making significant advances in providing effective treatments for patients with gastritis. Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited, and Sanofi are some of the key participants in this market.

Pfizer Inc. is a prominent participant on the global gastritis market, focusing on the development of innovative drugs and the delivery of high-quality healthcare solutions. The company offers both over-the-counter and prescription medications for the treatment of gastritis.

AstraZeneca plc is another market leader with a reputation for devising innovative medications and therapies for gastritis patients. Nexium, the primary product of the corporation, is among the most effective treatments for gastroesophageal reflux disease (GERD) and gastritis.

Johnson & Johnson is a global healthcare company that provides a variety of products and services to enhance the health and well-being of patients. With a focus on research and development, the company has created several new prescription medications and other treatments for gastritis.

Novartis AG is a multinational Swiss pharmaceutical corporation that develops and markets a variety of healthcare products and services. The company has a strong presence on the global gastritis market, with a concentration on developing innovative remedies with enhanced patient outcomes.

Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical corporation specializing in the development and marketing of healthcare-related products and services. Prevacid, the company's primary product, is widely regarded as one of the most effective gastritis treatments.

Sanofi is a global pharmaceutical company that develops and markets a wide variety of healthcare products and services. The company has a strong presence on the global gastritis market, focusing on the development of innovative treatments and the delivery of high-quality healthcare solutions.

Top Key Players in Gastritis Market

• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• AbbVie Inc.
• Bayer AG
• Eli Lilly and Company
• Novartis AG
• Merck & Co., Inc.
• Sanofi S.A.
• Johnson & Johnson
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Other Key Players

Recent Development

In 2021, The Global Gastritis Market is poised for a significant shakeup as a result of three noteworthy recent developments. AbbVie announced that it would acquire Allergan, a company specializing in the development and commercialization of therapies for a variety of conditions, including gastritis. This acquisition may result in the availability of new remedies for patients with gastritis.

In 2022, Johnson & Johnson made headlines when it acquired Momenta Pharmaceuticals, a company that specializes in developing remedies for rare diseases, including gastritis. With this acquisition, Johnson & Johnson intends to expand its treatment options for rare diseases, potentially to the benefit of those with gastritis.

In 2023, AstraZeneca announced that it is in Phase III clinical trials for a novel gastritis treatment that is presently in development. This drug could be a game-changer in the treatment of gastritis, offering patients new and more effective treatment options.

Report Scope: